[go: up one dir, main page]

MX2018004695A - Composiciones de proteinas estables. - Google Patents

Composiciones de proteinas estables.

Info

Publication number
MX2018004695A
MX2018004695A MX2018004695A MX2018004695A MX2018004695A MX 2018004695 A MX2018004695 A MX 2018004695A MX 2018004695 A MX2018004695 A MX 2018004695A MX 2018004695 A MX2018004695 A MX 2018004695A MX 2018004695 A MX2018004695 A MX 2018004695A
Authority
MX
Mexico
Prior art keywords
therapeutic biomolecule
biomolecule
therapeutic
porous structure
drug delivery
Prior art date
Application number
MX2018004695A
Other languages
English (en)
Other versions
MX390837B (es
Inventor
Chen Hunter
Schlesinger Erica
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2018004695A publication Critical patent/MX2018004695A/es
Publication of MX390837B publication Critical patent/MX390837B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/08—Polyethers derived from hydroxy compounds or from their metallic derivatives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describen formulaciones farmacéuticas estables y dispositivos de suministro de fármacos. En determinadas modalidades, el dispositivo de suministro de fármacos contiene un depósito cuando se implanta en un paciente que se encuentra en contacto parcial con el entorno del tejido. El depósito permanece en contacto con el entorno a través de una estructura porosa en el alojamiento del dispositivo de suministro. El depósito contiene una combinación de la biomolécula terapéutica y una segunda molécula que funciona para estabilizar y restringir la solubilidad de la biomolécula terapéutica, mediante lo cual se controla la cantidad de biomolécula terapéutica que se encuentra en solución. La concentración de la biomolécula terapéutica soluble o el tamaño del área de superficie de la estructura porosa controla la velocidad de suministro de la biomolécula terapéutica al tejido diana.
MX2018004695A 2015-10-16 2016-10-14 Composiciones de proteinas estables. MX390837B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562242412P 2015-10-16 2015-10-16
PCT/US2016/057019 WO2017066554A1 (en) 2015-10-16 2016-10-14 Stable protein compositions

Publications (2)

Publication Number Publication Date
MX2018004695A true MX2018004695A (es) 2019-03-14
MX390837B MX390837B (es) 2025-03-21

Family

ID=57209897

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018004695A MX390837B (es) 2015-10-16 2016-10-14 Composiciones de proteinas estables.
MX2022003376A MX2022003376A (es) 2015-10-16 2018-04-16 Composiciones de proteinas estables.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022003376A MX2022003376A (es) 2015-10-16 2018-04-16 Composiciones de proteinas estables.

Country Status (13)

Country Link
US (1) US20180289623A1 (es)
EP (1) EP3362041A1 (es)
JP (3) JP6853245B2 (es)
KR (1) KR102731879B1 (es)
CN (2) CN108348462B (es)
AU (2) AU2016340072B2 (es)
CA (1) CA3001346A1 (es)
EA (1) EA036623B1 (es)
IL (2) IL258570B2 (es)
MX (2) MX390837B (es)
MY (2) MY193964A (es)
WO (1) WO2017066554A1 (es)
ZA (1) ZA201802460B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11291636B2 (en) 2011-11-18 2022-04-05 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016340072B2 (en) * 2015-10-16 2021-10-28 Regeneron Pharmaceuticals, Inc. Stable protein compositions
AU2018368466B2 (en) * 2017-11-17 2024-06-20 Amgen Inc. VEGFR-Fc fusion protein formulations
LT4364724T (lt) 2018-05-10 2026-01-12 Regeneron Pharmaceuticals, Inc. Farmacinės formos, kurių sudėtyje yra didelės koncentracijos vegf receptoriaus sulietas baltymas
KR20200029374A (ko) * 2018-09-10 2020-03-18 삼성바이오에피스 주식회사 단백질을 포함하는 액상 조성물
CN112294760B (zh) * 2019-07-26 2025-12-12 宁波新致生物科技有限公司 一种液体制剂及其应用
WO2025235973A1 (en) * 2024-05-09 2025-11-13 Deep Brain Bci Corporation Implantable medical devices for delivering therapeutics and brain-computer interface systems

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5018693A (en) * 1992-09-21 1994-04-12 Upjohn Company, The Sustained-release protein formulations
US6004549A (en) * 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions
CA2512052C (en) * 2002-12-31 2016-06-21 Altus Pharmaceuticals Inc. Human growth hormone crystals and methods for preparing them
EP1635787B1 (en) * 2003-06-26 2011-12-14 Control Delivery Systems, Inc. Bioerodible sustained release drug delivery systems
CA2588449A1 (en) * 2004-11-24 2006-06-01 Therakine Corporation An implant for intraocular drug delivery
DK2364691T3 (da) * 2006-06-16 2013-07-01 Regeneron Pharma VEGF antagonist-formuleringer, der kan anvendes til intravitreal administration
WO2008109886A1 (en) 2007-03-08 2008-09-12 The Regents Of The University Of California Topographically engineered structures and methods for using the same in regenerative medicine applications
ES2558544T3 (es) 2007-03-16 2016-02-05 The Regents Of The University Of California Implantes médicos revestidos en la superficie de nanoestructura y métodos de empleo de los mismos
US8623395B2 (en) * 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
SG2014007389A (en) * 2009-01-29 2014-04-28 Forsight Vision4 Inc Posterior segment drug delivery
CN101559041B (zh) * 2009-05-19 2014-01-15 中国科学院过程工程研究所 粒径均一的多肽药物缓释微球或微囊制剂及制备方法
US8417452B2 (en) 2009-08-19 2013-04-09 General Motors Llc System for providing information to an operator of a vehicle
CN105435338B (zh) 2010-08-05 2019-03-26 弗赛特影像4股份有限公司 用于药物输送的注入器装置和方法
HRP20211909T1 (hr) 2010-08-05 2022-03-18 Forsight Vision4, Inc. Uređaj za liječenja oka
SG194155A1 (en) 2011-04-14 2013-11-29 Univ California Multilayer thin film drug delivery device and methods of making and using the same
IN2014DN10765A (es) 2012-05-30 2015-09-04 Univ California
US9463177B2 (en) 2012-09-10 2016-10-11 The Regents Of The University Of California Compounds and methods for modulating vascular injury
EP3929218A1 (en) * 2014-07-14 2021-12-29 Amgen, Inc Crystalline antibody formulations
KR101808234B1 (ko) * 2015-06-23 2017-12-12 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
AU2016340072B2 (en) * 2015-10-16 2021-10-28 Regeneron Pharmaceuticals, Inc. Stable protein compositions

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11291636B2 (en) 2011-11-18 2022-04-05 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles
US11951216B2 (en) 2011-11-18 2024-04-09 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles

Also Published As

Publication number Publication date
JP7179112B2 (ja) 2022-11-28
WO2017066554A1 (en) 2017-04-20
EA036623B1 (ru) 2020-12-01
ZA201802460B (en) 2024-09-25
CN113827704A (zh) 2021-12-24
JP7547438B2 (ja) 2024-09-09
CN113827704B (zh) 2024-07-12
JP2023025046A (ja) 2023-02-21
IL258570B2 (en) 2024-07-01
CN108348462A (zh) 2018-07-31
IL258570A (en) 2018-05-31
AU2016340072B2 (en) 2021-10-28
AU2022200475B2 (en) 2023-09-14
EP3362041A1 (en) 2018-08-22
JP2021098742A (ja) 2021-07-01
US20180289623A1 (en) 2018-10-11
CA3001346A1 (en) 2017-04-20
MX390837B (es) 2025-03-21
JP2018538243A (ja) 2018-12-27
KR102731879B1 (ko) 2024-11-20
MY199546A (en) 2023-11-06
IL310557A (en) 2024-03-01
BR112018007507A2 (pt) 2018-10-23
CN108348462B (zh) 2021-10-15
MX2022003376A (es) 2022-04-12
IL258570B1 (en) 2024-03-01
AU2016340072A1 (en) 2018-05-10
AU2022200475A1 (en) 2022-02-17
MY193964A (en) 2022-11-03
JP6853245B2 (ja) 2021-03-31
KR20180063311A (ko) 2018-06-11
EA201890979A1 (ru) 2018-10-31

Similar Documents

Publication Publication Date Title
MX2018004695A (es) Composiciones de proteinas estables.
BR112015022433A2 (pt) dispositivos de liberação de droga com componente permeável à droga e métodos
BR112016010103A8 (pt) métodos, kits e dispositivos de suprimento de fármaco osmótico.
CL2012002326A1 (es) Uso de una combinación de por lo menos un agente quimioterapéutico y una cantidad efectiva de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular), porque sirve para preparar un medicamento útil en el tratamiento de cáncer ovárico; y su kit para tratar el cáncer ovárico sin tratamiento anterior en una paciente humana.
CL2020001206A1 (es) Dispositivos de suministro de fármacos y métodos para uso con un catéter urinario.
MX2023007117A (es) Formulacion liquida para preparar un vehiculo de suministro que comprende un polimero termosensible y un polimero sensible a iones.
CY1122716T1 (el) Ρινικη συσταση κονεως για την αγωγη της υπογλυκαιμιας
UY30321A1 (es) Procedimiento para preparar medicamentos caracterizado por el uso de derivados sustituidos de la 3-metil-7-(2-butin-1-il) xantina y aplicaciones
AR100353A1 (es) Droga de direccionamiento a glipicano 3 (gpc3) que se administra a un paciente que responde a la terapia con drogas de direccionamiento a gpc3
WO2013078257A8 (en) Implantable solid-liquig drug delivery apparatus, formulations, and methods of use
MX2019003173A (es) Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada.
AR063571A1 (es) Aparato para el agregado de agentes o ingredientes solubles a un líquido portador, para su administración oral a través de un sorbete
EP4537830A3 (en) Bioerodible drug delivery devices
AU2017246889A8 (en) Implantable ocular drug delivery devices
GT201300292A (es) Formulaciones peptídicas de liberación controlada.
MX383085B (es) Dispositivo de entrega de fármacos expandibles y método de uso.
HRP20221252T1 (hr) Sustavi isporuke lijeka i postupci za liječenje raka mokraćnog mjehura s gemcitabinom
EA201692392A1 (ru) Новая лекарственная форма мелоксикама
DOP2017000055A (es) Tratamientos médicos a base de anamorelina
UY36202A (es) Composición farmacéutica que comprende hemoglobina recombinante o un agente terapéutico basado en subunidades para el tratamiento de cáncer
EA201992272A1 (ru) Ацилированное инсулиновое соединение
EP2745856A3 (en) Bioactive Compositions, Bioactive Eluting Devices and Methods of Use Thereof
EP4384232A4 (en) DRUG DELIVERY DEVICE WITH CANNULA HAVING BIOACTIVE AGENT
CO2017004442A2 (es) Dispositivo de inhalación
BR112021025291A2 (pt) Dispositivos de contenção de medicamento e composições associadas